DAFNA Capital Management »

Nektar Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Nektar Therapeutics (NKTR) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Nektar Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Nektar Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nektar Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $3.1M 55k 56.90
2025-06-30 $258k 10k 25.84

More positions owned by DAFNA Capital Management

Stereotaxis Com New (STXS)
Spdr S&p Biotech Etf Etf (XBI)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
AtriCure (ATRC)
Merus N V (MRUS)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ideaya Biosciences (IDYA)
Axogen (AXGN)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Arcus Biosciences Incorporated (RCUS)
Syndax Pharmaceuticals (SNDX)
Day One Biopharmaceuticals I (DAWN)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for DAFNA Capital Management

Top funds holding Nektar Therapeutics

Susquehanna International
BVF
Vanguard Group
Citadel Advisors
Farallon Capital Management
BlackRock
Millennium Management
Two Sigma Investments
Nantahala Capital Management
22NW
Emerald Advisers
Leucadia National Corporation
Dr. Jeffrey R. Jay, M.D.
PRIMECAP Management Company
Renaissance Technologies

View all funds holding Nektar Therapeutics